Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Down 46.4% in June

Marker Therapeutics, Inc. (NASDAQ:MRKR) saw a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 116,653 shares, a decrease of 46.4% from the June 15th total of 217,647 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average daily volume of 52,848 shares, the days-to-cover ratio is presently 2.2 days.

Institutional Trading of Marker Therapeutics

Several hedge funds have recently added to or reduced their stakes in MRKR. Jane Street Group LLC acquired a new position in Marker Therapeutics during the 4th quarter worth $60,000. Boyer Financial Services Inc. acquired a new position in shares of Marker Therapeutics during the fourth quarter valued at $57,000. LPL Financial LLC raised its stake in shares of Marker Therapeutics by 41.7% during the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock valued at $124,000 after purchasing an additional 24,500 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in Marker Therapeutics by 16.5% in the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after purchasing an additional 13,340 shares during the period. Finally, NewEdge Advisors LLC bought a new position in Marker Therapeutics in the 4th quarter valued at about $222,000. Institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Trading Down 2.2%

Marker Therapeutics stock traded down $0.03 during midday trading on Friday, reaching $1.31. 30,878 shares of the stock traded hands, compared to its average volume of 182,067. Marker Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $2.46. The firm has a market cap of $21.84 million, a price-to-earnings ratio of -2.15 and a beta of 1.45. The firm has a fifty day moving average price of $1.43 and a two-hundred day moving average price of $1.52.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.78 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%. Analysts anticipate that Marker Therapeutics will post -1.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MRKR. Weiss Ratings reissued a “sell (d-)” rating on shares of Marker Therapeutics in a report on Wednesday, June 24th. HC Wainwright restated a “buy” rating on shares of Marker Therapeutics in a research note on Wednesday, May 20th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Marker Therapeutics has a consensus rating of “Hold” and an average target price of $10.00.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.